Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review-Reference-Cited by-同舟云学术

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review

Published:2020-05-22 Issue:3 Volume:15 Page:279-299
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Thi Aye Myat^ORCID,Tin Tin Sandar,McKeage Mark,Elwood J. Mark

Funder

New Zealand ASEAN scholarship

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-020-00718-w.pdf

Reference54 articles.

1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1):8. https://doi.org/10.5334/aogh.2419.

2. Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther. 2017;102(5):757–64.

3. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai C, et al. Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595–605.

4. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–59.

5. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. Non-small cell lung cancer, Version 6. J Natl Compr Canc Netw. 2015;13(5):515–24.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimising primary molecular profiling in non-small cell lung cancer;PLOS ONE;2024-07-31

2. The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA;Heliyon;2024-05

3. Optimising primary molecular profiling in NSCLC;2023-08-21

4. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis;PharmacoEconomics - Open;2023-04-19

5. Lung cancer and inequalities in access to multidisciplinary lung cancer services;Inequalities in Respiratory Health;2023-03-01